| Similar Articles |
|---|
 |
The Motley Fool
June 16, 2005
Karl Thiel |
BiDil's Bid for a Narrow Label Although things appear to be going NitroMed's way, there is a dark horse spoiler looming in the shadows that should keep investors on their toes today. The company is seeking FDA approval for African-Americans only, but what if BiDil is given a broader label acceptance?   |
Bio-IT World
January 21, 2005 |
The Race Prescription Card The FDA is on the verge of approving a heart disease drug called BiDil that is particularly effective in African-Americans. Some see this as a an effort to address health inequalities while others view it as a first step en route to racial discrimination. |
BusinessWeek
June 27, 2005
Amy Barrett |
Color-Blind Drug Research Is Myopic Researchers will sometimes have to use the blunt instrument of race to help match patients with the right drugs. |
The Motley Fool
May 25, 2005
Karl Thiel |
A Gold Mine in Generics Will NitroMed's new math add up to investment success? |
The Motley Fool
August 2, 2004
W.D. Crotty |
NitroMed: The New Taser? A new cardiac drug springs this stock into an eye-opening run. |
